CardioNet is the most well-known company in the Mobile Cardiac Telemetry space for pioneering Mobile Cardiac Outpatient Telemetry or MCOT™. CardioNet can be crediting with virtually creating this form of Cardiac Monitoring technology as we have it today.
Starting back in 1999, CardioNet is the company that had the vision to take ambulatory monitoring to the next level. The company was founded on the concept to close the gap on technological limitations of traditional cardiac monitoring (Holter and Event monitoring) to be able to monitor their patient’s heart beat (in real-time) on a beat by beat basis 24 hours a day, 7 days a week, 365 days a year. CardioNet opened its first diagnostic laboratory in 2002 in Philadelphia, PA and now traded on the NASDAQ (BEAT) under the holding company Bio Telemetry.
To CardioNet, ‘time is of the essence’ when diagnosing patients with significant cardiac arrhythmic disturbances. The MCOT™ technology from CardioNet was the first to offer reliable real-time ECG monitoring solution where 24-48 Hour Holter monitoring & loop recording was not sufficient in capturing relevant clinical information.
Competitive Advantage – MCOT™
When we speak of CardioNet as the pioneer, we can also credit them as the company that published the clinical work and brought reimbursement to Mobile Cardiac Telemetry studies in the U.S. With most emerging technologies, the phrase ‘the early bird gets the worm’ sums up the leadership of CardioNet’s in the Mobile Cardiac Telemetry market segment. CardioNet has a sound reputation for reliable service, advancing technology and a commitment to reducing healthcare costs related to ambulatory cardiac monitoring.
Although CardioNet remains the U.S leader by being the first to provide MCT technology, other companies are now introducing newer technology with comparable monitoring and service capabilities. CardioNet relies on their brand name & their clinical strength (proven in published clinical studies) to separate their company among the competition.
MCOT™ Device Technology
As we discussed, CardioNet was the inventor of Mobile Cardiac Outpatient Telemetry. With them being in the MCT business the longest, they have made several different models for their Mobile Cardiac Outpatient Telemetry monitors. CardioNet originated a service company which has evolved into the industry giant with the acquisitions of prominent cardiac monitoring companies such as Braemar Instruments, Mednet Healthcare Technologies & Biomedical Systems’ (BMS) service division.
CardioNet now claims to have the best MCT technology with their newest MCOT™ device. This unit is slightly smaller in size & weight with 2 functioning modules. The new MCOT™ device has a smaller sensor connected to patient leads (electrodes) that sends the ECG data via wireless transmission to the communication device (phone). The communication device then transmits the relevant ECG data (via cellular technology) in real time to the CardioNet laboratory. For more information, click CardioNet MCOT® device.
Independent Diagnostic Testing Facility (IDTF) in Pennsylvania.
Legal & Safety Notice
CardioNet (BioTelemetry and its subsidiaries) have a remarkable track record for their manufacturing & regulatory processes. All of the CardioNet technology have the most credible approvals in the U.S and worldwide.
CardioNet has dominated the headlines with several lawsuits and acquisitions. CardioNet has initiated several lawsuits against competitors for violations of their patents & their proprietary MCOT™ technology. CardioNet recently won a significant suit against Mednet Healthcare Technologies for patent infringement on 5 accounts. The result ended in a acquisition of Mednet which has sent sound waves among Mobile Cardiac Telemetry companies in the industry. CardioNet is still involved in a pending suit against Scottcare for similar patent infringement.